Clinical Trial Update: Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET)

View source ↗

Summary

Clinical trial update reporting completion of an imaging study using AUY922, an HSP90 inhibitor, with VEGF-89Zr-bevacizumab PET in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Luminespib (AUY922) (luminespib)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Breast Cancer | Status: COMPLETED